Apply for Perjeta (Pertuzumab) Copay Assistance Now

Photo Of 2 Doctors

When will Perjeta be released as a generic?

This medication is projected to be released in generic form June 2024. However, this timeframe is currently not guaranteed and may be pushed back as far as 2025. When it is released, we will ensure that our current Perjeta patients are the first to know. Keep your prescription with QuickRx and you’ll never have to worry about whether you’re getting the absolute best prices.
If you have pressing questions call us for immediate assistance (347) 691-3494


What is Perjeta?

Perjeta (generic name: pertuzumab) is a medication used in combination with other drugs to treat certain types of breast cancer. It belongs to a class of medications known as HER2 inhibitors, working by targeting specific proteins to block the growth of cancer cells that overexpress the HER2 gene. Perjeta is typically used in combination with chemotherapy and another HER2-targeted medication for the treatment of HER2-positive metastatic breast cancer or as an adjuvant treatment in early-stage breast cancer to help prevent its recurrence.

What If I miss a dose of Perjeta (Pertuzumab)?

The course of action for a missed dose of Perjeta depends on how long it has been since the last dose was taken. If a dose of Perjeta (Pertuzumab) is missed, it’s essential to contact a healthcare professional promptly for guidance. The healthcare provider will offer specific instructions on when and how to take the missed dose, depending on the treatment schedule. It’s crucial to avoid doubling the dose to make up for the missed one unless instructed by a healthcare professional.

What are the potential side effects of Perjeta?

Perjeta (pertuzumab) may cause various side effects, ranging from common to more severe reactions. Common side effects can include diarrhea, nausea, fatigue, hair loss, headache, and muscle pain. More serious side effects might involve heart problems, such as a decreased heart function known as heart failure, allergic reactions, infusion reactions, and potentially severe diarrhea. It’s essential to promptly inform a healthcare professional if experiencing any side effects while on Perjeta for appropriate evaluation and guidance.

Are there any drug interactions with Lonsurf (Trifluridine plus Tipiracil?

Lonsurf (Trifluridine plus Tipiracil) may interact with other medications, potentially affecting their efficacy or increasing the risk of side effects. Some notable drug interactions include:

  1. Warfarin or other anticoagulants: Lonsurf may increase the risk of bleeding when used concomitantly with anticoagulant medications. Monitoring of blood clotting parameters may be necessary, and the dosage of anticoagulants may need adjustment.
  2. Fluoropyrimidines (e.g., fluorouracil): Concomitant use of Lonsurf with other fluoropyrimidines may increase the risk of toxicity, and caution should be exercised when combining these medications.
  3. Uridine triacetate: Uridine triacetate, used to treat overdose or severe toxicity from fluoropyrimidine chemotherapy, may interact with Lonsurf. Using them together may reduce the effectiveness of uridine triacetate.
  4. CYP2D6 substrates: Tipiracil, one of the components of Lonsurf, may inhibit CYP2D6 enzyme activity. Therefore, medications metabolized by CYP2D6, such as certain antidepressants (e.g., fluoxetine, paroxetine), may have altered levels when used with Lonsurf.

Always inform your healthcare provider about all medications, including prescription, over-the-counter, herbal supplements, and vitamins, that you are taking before starting Lonsurf. This helps in identifying and managing potential drug interactions effectively. Adjustments in dosages or the need for alternative medications might be considered to minimize the risk of adverse effects or reduced efficacy.

What happens if I overdose?

Seek emergency medical attention or call the Poison Help line immediately at 1-800-222-1222.